Education
About Us
Working with TipRanks
Follow Us
DaVita (DVA)
NYSE:DVA
DVA Stock Chart & Stats
$115.20
$0.74(0.48%)
At close: 4:00 PM EST
$115.20
$0.74(0.48%)
Day’s Range― - ―
52-Week Range$113.97 - $179.60
Previous CloseN/A
Volume85.32K
Average Volume (3M)909.44K
Market Cap
$8.13B
Enterprise Value$23.67B
Total Cash (Recent Filing)$736.48M
Total Debt (Recent Filing)$14.88B
Price to Earnings (P/E)11.9
Beta0.52
Next Earnings
Feb 18, 2026EPS Estimate
3.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.51
Shares Outstanding70,600,000
10 Day Avg. Volume787,082
30 Day Avg. Volume909,437
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)104.94
Price to Sales (P/S)0.99
P/FCF Ratio8.67
Enterprise Value/Market Cap2.91
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit5.56
Enterprise Value/Ebitda9.47
Forecast
1Y Price Target
$136.50Price Target Upside18.49% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)10.57
Revenue Forecast (FY)$13.52B
Bulls Say, Bears Say
Bulls Say
Cost ManagementPatient care cost performance and international expected to offset.
Guidance AchievementManagement is navigating the challenges and achieving FY25 guidance.
Operating Income BenefitDVA continues to expect a $50m FY25 operating income benefit from oral phosphate binders.
Bears Say
Cyberattack ImpactManagement pointed to the cyberattack earlier in the year contributing to an elevated missed treatment rate in the quarter.
Earnings MissDVA missed 3Q25 EBIT by -10%, but we attribute a portion to Street mis-modeling.
Volume OutlookThe recent pullback has DVA shares looking more appealing, but a continued tepid volume outlook offsets upside.
DaVita News
DVA FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest stock price was $113.97 and its highest was $179.60 in the past 12 months.
What is DaVita’s market cap?
DaVita’s market cap is $8.13B.
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is Feb 18, 2026 which is in 59 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on Oct 29, 2025. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.221 by -$0.711.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Undervalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate is 3.24.
How many shares outstanding does DaVita have?
DaVita has 70,600,000 shares outstanding.
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of $2.51 in its last earnings report, missing expectations of $3.221. Following the earnings report the stock price went down -6.171%.
Which hedge fund is a major shareholder of DaVita?
Currently, no hedge funds are holding shares in DVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DaVita Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$136.50 (18.49% Upside)
$136.50 (18.49% Upside)
Blogger Sentiment
Bullish
DVA Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.30%
Trailing 12-Months
Company Description
DaVita
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DVA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a balanced sentiment with consistent financial performance and strategic investments in technology and clinical research as highlights. However, challenges such as a decline in treatment volumes and issues with integrated kidney care present notable lowlights.View all DVA earnings summariesDVA Revenue Breakdown
88.32% U.S. dialysis
11.68% Ancillary services
DVA Stock 12 Month Forecast
Average Price Target
$136.50
▲(18.49% Upside)
Technical Analysis
Fresenius Medical Care
―
HCA Healthcare
―
Encompass Health
―
Tenet Healthcare
―
The Ensign Group
―
Ownership Overview
Currently, No data available
---